Search All UT System Experts

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: A phase I/II randomized trial

Teresa Moran, Enriqueta Felip, Vicki Keedy, Hossein Borghaei, Frances A. Shepherd, Amelia Insa, Holly Brown, Timothy Fitzgerald, Sriram Sathyanarayanan, John F. Reilly, David Mauro, Karl Hsu, Li Yan, David H. Johnson

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: A phase I/II randomized trial'. Together they form a unique fingerprint.

Medicine & Life Sciences